Steven Kelly joins BioVex
This article was originally published in Scrip
BioVex, a US-based biotechnology company developing biologics for the treatment and prevention of cancer and infectious diseases, has appointed Steven Kelly chief commercial officer. He will be responsible for the company's commercial activities as it prepares for the potential launch of its investigational product, OncoVEX GM-CSF. Mr Kelly was most recently CEO of the oncology drug development company Innovive Pharmaceuticals. Before that, he was head of oncology marketing at Sanofi-Aventis.